Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027144 | 0.88 | MAPT (0.49) | MAPTLMNARAB9AL3MBTL1KMT2A | |
| SCHEMBL6027093 | 0.88 | MRGPRX4 (0.55) | MAPTLMNARAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL21798491 | 0.87 | RAB9A (0.72) | MAPTLMNARAB9AL3MBTL1KMT2A | |
| SCHEMBL23383954 | 0.87 | MAOB (0.53) | MAPTLMNARAB9AL3MBTL1KMT2A | |
| Tucaresol SCHEMBL29400654 | 0.85 | RXRA (0.56) | MAPTRAB9AKMT2ASMN1; SMN2HPGD | |
| Tucaresol SCHEMBL600942 | 0.85 | RXRA (0.56) | MAPTRAB9AKMT2ASMN1; SMN2HPGD | |
| SCHEMBL24702757 | 0.85 | RAB9A (0.49) | MAPTLMNARAB9AL3MBTL1KMT2A | |
| SCHEMBL21383460 | 0.83 | LMNA (0.43) | MAPTLMNARAB9AL3MBTL1KMT2A | |
| SCHEMBL24703158 | 0.83 | RAB9A (0.49) | MAPTLMNARAB9AL3MBTL1KMT2A | |
| SCHEMBL21383365 | 0.83 | MAPT (0.42) | MAPTLMNARAB9AL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778155-B | Tucarbaryl derivatives and uses thereof | 大连万春布林医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20220387365-A1 | TUCARESOL DERIVATIVES AND USES THEREOF | BEYONDSPRING PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220387365-A1 | TUCARESOL DERIVATIVES AND USES THEREOF | BEYONDSPRING PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-4058427-A1 | TUCARESOL DERIVATIVES AND USES THEREOF | Beyondspring Pharmaceuticals Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021096811-A1 | TUCARESOL DERIVATIVES AND USES THEREOF | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021096811-A1 | TUCARESOL DERIVATIVES AND USES THEREOF | BEYONDSPRING PHARMACEUTICALS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| CN-112778155-A | Turcatecol derivatives and uses thereof | 万春药业公司 | 2021-05-11 | — | — | CN | disclosed |
| US-9365532-B1 | Synthesis, composition and use of novel therapeutic and cosmetic Schiff base products formed by reaction of a carbonyl containing moeity with a transimination nucleophilic catalyst and the use of transimination nucleophilic catalysts to increase the rate at which carbonyl containing therapeutic and cosmetic actives form Schiff base products with biological amines | Nanometics, LLC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-1539723-B1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ASTRAZENECA (SE) | 2006-05-18 | — | — | US | disclosed |
| EP-1539723-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004016600-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ITK, WEE2, WEE1 | MAPT 3300/4885LMNA 1458/4885RAB9A 3095/4885 |
| US-20220387365-A1 | TUCARESOL DERIVATIVES AND USES THEREOF | ICOS, TEX264, PBK | MAPT 1181/4885LMNA 4819/4885RAB9A 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.